echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes Obes Metab: Liraglutide and oral hypoglycemic agents as an add-on therapy to maintain glycemic control in type 2 diabetic patients taking metformin alone

    Diabetes Obes Metab: Liraglutide and oral hypoglycemic agents as an add-on therapy to maintain glycemic control in type 2 diabetic patients taking metformin alone

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Since most type 2 diabetes (T2D) patients are treated in primary care, primary care clinicians play a key role in optimizing diabetes management


    The improvement and maintenance of glucose control is related to stronger compliance with hypoglycemic therapy.


    Primary endpoint: the time between two scheduled consecutive follow-ups after the 26th week to insufficient blood glucose control (HbA1c> 7.


    Results: Among the randomized patients (liraglutide, n=996; OAD, n=995), 47.


    The median time of poor glycemic control in patients with liraglutide was 44 weeks and 65 weeks compared with OAD.


    Figure 1 OAD, 4.


    Figure 1 OAD, 4.


    Table 1 The duration of treatment with liraglutide and OAD and the duration of premature discontinuation

    Table 1 The duration of treatment with liraglutide and OAD and the duration of premature discontinuation

    Table 2 Changes in clinical variables from baseline at 104 weeks or when treatment is stopped prematurely

    Table 2 Changes in clinical variables from baseline at 104 weeks or when treatment is stopped prematurely

    Table 3 Treatment of emergency serious adverse events (SOC and ≥1% of patients in any group)

    Table 3 Treatment of emergency serious adverse events (SOC and ≥1% of patients in any group)

    Figure 2 Kaplan-Meier time chart of liraglutide treatment to insufficient blood glucose control and post-event OAD subgroup*


    Figure 2 Kaplan-Meier time chart of liraglutide treatment to insufficient blood glucose control and post-event OAD subgroup*


    Compared with OAD, liraglutide can better maintain blood sugar control and supports the use of liraglutide in intensive treatment of T2D patients


     Unger J, Allison DC, Kaltoft M, et al.


    Maintenance of Glycemic Control with Liraglutide versus Oral Antidiabetic Drugs as Add-on Therapies in Patients with Type 2 Diabetes Uncontrolled with Metformin Alone: ​​A Randomized Clinical Trial in Primary Care (LIRA-PRIME).


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.